Abstract:Abstract Objective To evaluate the excess risk and relative hazards for developing incident clinical sequelae after the acute phase of SARS-CoV-2 infection in adults aged 18-65. Design Retrospective cohort study. Setting Three merged data sources from a large United States health plan: a large national administrative claims database, an outpatient laboratory testing database, and an inpatient hospital admissions database. Participants Individuals aged 18-65 with continuous enrollment in the health plan from January 2019 to the date of a diagnosis of SARS-CoV-2 infection. Three comparator groups, matched by propensity score, to individuals infected with SARS-CoV-2: a 2020 comparator group, an historical 2019 comparator group, and an historical comparator group with viral lower respiratory tract illness. Main outcome measures More than 50 clinical sequelae after the acute phase of SARS-CoV-2 infection (defined as the date of first SARS-CoV-2 diagnosis (index date) plus 21 days) were identified using ICD-10 (international classification of diseases, 10th revision) codes. Excess risk in the four months after acute infection and hazard ratios with Bonferroni corrected 95% confidence intervals were calculated. Results 14% of adults aged ≤65 who were infected with SARS-CoV-2 (27 074 of 193 113) had at least one new type of clinical sequelae that required medical care after the acute phase of the illness, which was 4.95% higher than in the 2020 comparator group. The risk for specific new sequelae attributable to SARS-Cov-2 infection after the acute phase, including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety, and fatigue, was significantly greater than in the three comparator groups (2020, 2019, and viral lower respiratory tract illness groups) (all P<0.001). Significant risk differences because of SARS-CoV-2 infection ranged from 0.02 to 2.26 per 100 people (all P<0.001), and hazard ratios ranged from 1.24 to 25.65 compared with the 2020 comparator group. Conclusions The results indicate the excess risk of developing new clinical sequelae after the acute phase of SARS-CoV-2 infection, including specific types of sequelae less commonly seen in other viral illnesses. Although individuals who were older, had pre-existing conditions, and were admitted to hospital because of covid-19 were at greatest excess risk, younger adults (aged ≤50), those with no pre-existing conditions, or those not admitted to hospital for covid-19 also had an increased risk of developing new clinical sequelae. The greater risk for incident sequelae after the acute phase of SARS-CoV-2 infection is relevant for healthcare planning.

Risk of herpes zoster in adults with SARS-CoV-2 infection in Spain: a population-based, retrospective cohort study

Long‐term risk of herpes zoster following COVID‐19: A retrospective cohort study of 2 442 686 patients

Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection

Host susceptibility to severe COVID-19: a retrospective analysis of 487 case outside Wuhan

The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine

Association of Human Leukocyte Antigen Alleles with COVID-19 Severity and Mortality in a Spanish Population

The Risk of Herpes Zoster in Women with Polycystic Ovary Syndrome: A Retrospective Population-Based Study

Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts

The Impact of the COVID-19 Pandemic on the Incidence of Herpes Zoster: A Narrative Literature Review

Mental health and risk of death and hospitalization in COVID–19 patients. Results from a large-scale population-based study in Spain

Impact of Respiratory Syncytial Virus (RSV) in adults 60 years and older in Spain.

Association between a History of herpes zoster and the risk of Sjögrens syndrome: a nationwide, population-based, case-control study

The risk of herpes zoster is positively associated with obesity, especially morbid obesity

The Burden of Herpes Zoster on Hospital Admissions: A Retrospective Analysis in the Years of 2015–2021 from the Abruzzo Region, Italy

Increased Risk of Herpes Zoster in Rheumatoid Arthritis Not Only Due to JAK Inhibitors—Study of 392 Patients from Single University Center

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2

A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination

Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study

Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan

Hospitalisation for herpes zoster in people with and without diabetes: A 10-year-observational study

The causal association between COVID-19 and herpes simplex virus: a Mendelian randomization study